Factors affecting lymph node yield in patients undergoing axillary node dissection for primary breast cancer: A single-institution review

Annals of Surgical Oncology

Volumn 19, Issue 6, 2012, Pages 1818-1824

  Lee, Marie Catherine ^a   Plews, Robert ^b   Rawal, Bhupendra ^a   Kiluk, John V ^a   Loftus, Loretta ^a   Laronga, Christine ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; AXILLARY LYMPH NODE EXTIRPATION; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; PRIMARY TUMOR; REVIEW; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84865134105     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2199-9     Document Type: Review

References (16)

1. Jacquillat C, Baillet F, Auclerc G, et al. Neoadjuvant chemotherapy of breast cancer. Drugs Exp Clin Res. 1986;12:147-52. (Pubitemid 16149886)
2. Swain S, Sorace R, Bagley C, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmeta-static breast cancer. Cancer Res. 1987;47:3889-94. (Pubitemid 17105745)
3. Schwartz G, Cantor R, Biermann W. Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast. Arch Surg. 1987;122:1430-4. (Pubitemid 18058294)
4. Mieog JSD, van Der Hage JA, van de Velde CJH. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94: 1189-200. (Pubitemid 47584766)
5. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-85. (Pubitemid 28363030)
6. Neuman H, Carey LA, Ollila DW, et al. Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg. 2006;191:827-9. (Pubitemid 43729388)
7. Belanger J, Soucy G, Sideris L, et al. Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count. J Am Coll Surg. 2008;206:704-8. (Pubitemid 351443106)
8. Baslaim MM, Al Malik OA, Al-Sobhi SS, et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. Am J Surg. 2002;184:299-301. (Pubitemid 35287345)
9. NCCN guidelines in oncology. Breast cancer, version 1.2009. 2009. http://www.nccn.org.
10. Axelsson C, Mouridsen H, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer. 1992;28A:1415-8.
11. Sosa J, Diener-West M, Gusev Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol. 1998;5:140-9. (Pubitemid 29071283)
12. Mathiesen O, Carl J, Bonderup O, et al. Axillary sampling and the risk of erroneous staging of breast cancer. An analysis of 960 consecutive patients. Acta Oncol. 1990;29:721-5. (Pubitemid 20354520)
13. Kjaergaard J, Blichert-Toft M, Andersen J, et al. Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer. Br J Surg. 1985;72:365-7. (Pubitemid 15034707)
14. World Health Organization Global Database on Body Mass Index. Updated January 17, 2011. http://apps.who.int/bmi/index.jsp? introPage=intro-3.html.
15. Edge SB, Byrd DR, Compton CC, et al. editors. AJCC cancer staging manual, vol. 1. New York: Springer, 2010.
16. Boughey JC, Donohue JH, Jakub JW, et al. Number of lymph nodes identified at axillary dissection. Cancer. 2010;116:3322-9.